论文部分内容阅读
目的:探讨茵陈色原酮(capillarisin,Cap)对结肠癌细胞增殖及迁移能力的影响及其机制。方法:采用不同浓度的Cap体外干预结肠癌细胞SW620及正常结肠细胞FHC,CCK-8比色法检测细胞增殖活性,Transwell迁移实验检测细胞迁移能力,实时定量PCR(q PCR)法检测癌基因(K-ras、c-Src、c-Myc)的m RNA表达,Western blot检测细胞上皮-间质转化(EMT)标志蛋白(Ecadherin、Vimentin)表达。结果:与DMSO对照组相比,各组Cap可显著抑制结肠癌细胞SW620增殖活性及迁移细胞数(P<0.05),但对正常结肠细胞FHC增殖及迁移作用无显著差异(P>0.05);与5-FU组相比,各组Cap对于正常结肠细胞FHC的增殖及迁移活性抑制作用显著减小(P<0.05)。与DMSO对照组相比,各组Cap可显著降低结肠癌细胞K-ras、c-Src、c-Myc的m RNA水平。与DMSO对照组相比,Cap高剂量组可提高结肠癌细胞上皮标志物E-cadherin蛋白表达,降低间质标志物Vimentin蛋白表达。结论:Cap可能通过抑制癌基因(K-ras、c-Src、c-Myc)m RNA表达抑制结肠癌细胞增殖,通过逆转EMT过程抑制结肠癌细胞转移。与5-FU相比,Cap可能具有更好的应用安全性,具有开发为新一代天然抗肿瘤单体药物的前景。
Objective: To investigate the effect and mechanism of capillarisin on the proliferation and migration of colon cancer cells. Methods: The proliferation of human colon cancer cell line SW620 and normal colon cell FHC and CCK-8 were detected by different concentrations of Cap in vitro. The cell migration ability was detected by Transwell migration assay. The real-time quantitative PCR (q PCR) M-ras, c-Src and c-Myc) were detected by Western blot. The expression of EMT marker protein (Vimentin) was detected by Western blot. Results: Compared with DMSO control group, Cap significantly inhibited the proliferation and migration of colon cancer cell line SW620 (P <0.05), but had no significant difference on the proliferation and migration of FHC in normal colon cells (P> 0.05). Compared with 5-FU group, the inhibitory effect of Cap on the proliferation and migration of FHC in normal colon cells was significantly reduced (P <0.05). Compared with the DMSO control group, each group Cap significantly reduced the mRNA levels of K-ras, c-Src and c-Myc in colon cancer cells. Compared with the DMSO control group, Cap high-dose group could increase the E-cadherin protein expression of colon cancer cell epithelial marker and decrease the expression of Vimentin protein. CONCLUSION: Cap may inhibit the proliferation of colon cancer cells by inhibiting the expression of oncoproteins (K-ras, c-Src, c-Myc) and inhibit the metastasis of colon cancer cells by reversing the EMT process. Compared with 5-FU, Cap may have better application safety and promise to be developed into a new generation of natural anti-tumor monomeric drugs.